Our role and vision in the psychedelic renaissance
There is an ongoing psychedelic renaissance in the Western world linked to a rekindled scientific interest in the psychedelic experience. The first psychedelic treatment methods will probably be approved within a year or so, which could be the first step for a paradigm shift in psychiatry. At the same time, we are facing a series of challenges linked to a lack of experience and knowledge about how the potential can be extracted in the best way. These substances have been used by humans for spiritual and medicinal purposes for thousands of years, but in our culture this is something completely new.
The seed for Nysnö was already planted in 2016, when our co-founders Filip, Johan and Jesper helped form the Network for Psychedelic Science. The intention since then has been to contribute to a future for psychedelic-assisted therapy in Sweden by increasing the level of knowledge and breaking a cultural stigma. Our work resulted in Sweden's first scientific conference on psychedelic psychiatry at the highest international level in 2018 and the approval of the first clinical study with psilocybin for depression in 2020. Nysnö took shape in 2021 and represents the next step in the process that we believe is necessary to contribute to a responsible and successful integration of psychedelic treatment models in Sweden and the world.
Our vision is to be a global knowledge company with excellence in the application of psychedelics in the fields of mental illness and personal development. We do this by offering a comprehensive program based on our own model that includes legal psychedelic sessions with psilocybin, through training in the psychedelic research field, as well as by contributing to both research and the general social debate.
We have collected the most common questions here, but you are also welcome to email us at info@nysno.se.